Tilray Brands, Inc. has confirmed that FL Group S.R.L., a division of Tilray Medical in Italy, has received approval to import and distribute Tilray’s medical cannabis oral solution THC25 across the country.
Approval was received from the Italian Ministry of Health. In Italy, where medical cannabis authorisation is limited, Tilray Medical has an established national pharmaceutical distribution network with FL Group to distribute Tilray’s THC25 medical cannabis oral solution.
Patients may obtain prescriptions for Tilray and other medical cannabis products in Italy through their medical doctor.
Read more: Tilray Medical granted market authorisation in Poland
Tilray’s Chief Strategy Officer and Head of International Business, Denise Faltischek, said “Expanding our approved authorisation into Italy once again proves our commitment to be the most responsible, trusted and market leading cannabis company in the world with a portfolio of innovative and high-quality products that address the needs of the patients and consumers we serve.
“We remain dedicated and focused on working with regulators across international markets to advocate for responsible cannabis regulations, best practices, and a reliable source of quality products.”
The company currently provides EU-GMP certified medical cannabis products in 22 countries with a comprehensive portfolio of THC and CBD products.
The company states that each medical cannabis product that it offers has been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products.
[activecampaign form=31]
